報價延遲最少15分鐘:2025/08/17 16:27 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.2 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-42.65/-14.40
|
|
企業價值
38.20M
|
| 資產負債 |
|
每股賬面淨值
-1.73
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
57.34K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/17 16:27 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Hyperion DeFi Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of noveland existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or New combinations. |
